von Willebrand disease
Upcoming SlideShare
Loading in...5
×
 

von Willebrand disease

on

  • 984 views

Short review of vWD for medical student and resident

Short review of vWD for medical student and resident

Statistics

Views

Total Views
984
Slideshare-icon Views on SlideShare
984
Embed Views
0

Actions

Likes
1
Downloads
30
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

CC Attribution-NonCommercial-ShareAlike LicenseCC Attribution-NonCommercial-ShareAlike LicenseCC Attribution-NonCommercial-ShareAlike License

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    von Willebrand disease von Willebrand disease Presentation Transcript

    • von WillebranddiseaseKaipol Takpradit
    • ● Introduction to von Willebrand factor● von Willebrand disease● ​Type of von Willebrand disease● ​Management of von Willebrand diseaseTopic
    • ● Named after Dr. Erik von Willebrand whodescribe hereditary bleeding disorderdistinguished from hemophilia in 1924● ​The protein was purified in 1970s● ​Produced in megakaryocyte, endothelium,subendothelial CNT● ​Size 250 kDa for monomer and up tomore than 20,000 kDa for multimervon Willebrand factor
    • ● Has functions of binding for platelet, FVIII,and collagen● Bind platelet to exposed collagen● Chaperone of FVIII● Cleaved by ADAMTS-13 protein at A2domain and eliminated by liver and spleenvon Willebrand factor
    • von Willebrand factorFVIII chaperonePlatelet GPIb bindingADAMTS-13 cleavage siteCollagen binding GPIIbIIIa binding
    • von Willebrand disease● Manifestation of platelet binding problem orseverely decrease FVIII half life● Present with mucocutaneous bleeding● Or hemophilia-like in type 2N and type 3● History of bleeding diathesis in first-degreerelatives● Significant bleeding may be determined bybleeding score of 3 in male and 5 in female
    • Bleeding scoreBowman M, et al. J Thromb Haemost. 2008:6(12);2062-66.
    • ●​Type 1: vary degree of decrease, vWF:Rco/vWF:Ag > 0.6●​Type 1 Vicenza: normal production andsecretion of vWF but has increaseexcretion●​A person with blood group O has lowervWF level than other ABO blood group​Type of von Willebrand disease
    • ●​Type 2: abnormal function○ ​ 2A: decreased larger multimer, vWF:Rco/vWF:Ag < 0.6○ ​2B: increase affinity to platelet, hyper-response to RIPA○ ​2M: decrease affinity to platelet GPIb○ ​2N: decrease affinity to FVIII, FVIII:c/vWF:Ag< 0.5●​Type 3: severe or totally absence of vWFType of von Willebrand disease
    • ●​The goal is to prevent bleeding●​Identify patients with increased bleedingrisk●​Patients with vWF level > 40 UI/dL orwithout history of bleeding are not at riskof bleeding●Desmopressin is the first line of treatmentManagement of vWD
    • Management of vWD●​Desmopressin infusion trial can determineresponse of the patient●If vWF:Rco/Ag near normal and level > 30UI/dL with low bleeding risk usuallyresponse to desmopressin●​For patients with type 2b or type 3 andpatients who do not respond todesmopressin factor replacement isrequired​
    • ●​Increase vWF secretion from endothelialWeibel-Palade bodies or from platelet α-granule●Dose 0.3 mcg/kg IV or SC●​150-300 mcg intranasal●​Check for level at 1 and 4 hr to access theresponse●​​Repeat at 12-24 hr up to 3-4 doses●​Tachyphylaxis after continuous dose●​Fluid pretension must be aware offDesmopressin infusion trial
    • Replacement therapy● vWF hemostat level 20-50%,half life 20-40hr● Use FVIII conc. that contain vWF 40-60 U/kgthen 40-50 U/kg q 12-24 hr up to 7 days● Cryoprecipitate 1 U/ 10 kg OD
    • Antifibrinolytic● Tranexamic acid may help in case of minorbleeding for hypermenorrhea● Dose 25 MKDose for oral and 10 MKDosefor IV 3-4 times/day● Renal impairment require dose reduction● Should be avoid in patient with highcardiovascular risk
    • For pregnancy● vWF usually increase in near-term period● Serial checking in the last trimester isrecommended● Desmopressin can be administered rightafter an umbilical cord is cut● Replacement immediately (40-50 U/kg)before delivery and at 24 and 72 hr later (20-30 U/kg)● Antifibrinolytic can relieve excessive lochia
    • Inheritance● Autosomal Dominant● Except type 2n, 3 -> autosomal recessive
    • Question?FIN